THN102 (Flecainide and Modafinil), Emerging Drug Insight and Market Forecast - 2032

“THN102 (Flecainide and Modafinil), Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about THN102 (Flecainide and Modafinil) for Excessive Daytime Sleepiness (EDS) in the 7MM. A detailed picture of the THN102 (Flecainide and Modafinil) for Excessive Daytime Sleepiness (EDS) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the THN102 (Flecainide and Modafinil) for Excessive Daytime Sleepiness (EDS) . The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the THN102 (Flecainide and Modafinil) market forecast, analysis for Excessive Daytime Sleepiness (EDS) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Excessive Daytime Sleepiness (EDS) .

Drug Summary

THN102 combines modafinil, the first line of current treatment for narcolepsy, and flecainide, a repositioned drug that acts on glial cells. It resulted in positive Phase IIa results concerning efficacy (improvement in patients on the Epworth scale) and safety (excellent tolerance).

It has already completed Phase II in patients with narcolepsy, which aimed to demonstrate the superiority of THN102 compared to the reference treatment (modafinil) in a patient population of narcoleptics already treated with modafinil, and who, despite this treatment, showed residual disabling drowsiness. The safety and tolerance profile of THN102 were considered very satisfactory. However, the results do not show any difference in effectiveness between THN102 and modafinil alone on the study's primary endpoint.

THN102 aims to become the reference treatment for Excessive Daytime Sleepiness (EDS) in Parkinson's disease. It has been evaluated in Phase II in patients with daytime sleepiness in Parkinson's disease, and its efficacy has been demonstrated compared to placebo. The THN102 is the subject of intellectual property reinforced and is covered by a family of patents expiring in 2034.

In June 2018, Theranexus announced the publication of a scientific article on the mechanism of action of its flagship drug candidate THN102 in the scientific journal published by the International College of Neuropsychopharmacology.

The study has established the effect of drug candidate THN102 on brain metabolic activity using an approved imaging technique called positron emission tomography, with radiolabelled glucose (fludeoxyglucose or FDG). It demonstrated that administration of THN102 intensifies metabolic activity in comparison to modafinil alone, in the areas involved in regulating sleep-wake cycles and cognitive functions, and more specifically, the cortex, amygdala and striatum, a reflection of the activation of these anatomical structures by THN102.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the THN102 (Flecainide and Modafinil) description, mechanism of action, dosage and administration, research and development activities in Excessive Daytime Sleepiness (EDS).
• Elaborated details on THN102 (Flecainide and Modafinil) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the THN102 (Flecainide and Modafinil) research and development activity in Excessive Daytime Sleepiness (EDS) in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around THN102 (Flecainide and Modafinil).
• The report contains forecasted sales of THN102 (Flecainide and Modafinil) for Excessive Daytime Sleepiness (EDS) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Excessive Daytime Sleepiness (EDS).
• The report also features the SWOT analysis with analyst views for THN102 (Flecainide and Modafinil) in Excessive Daytime Sleepiness (EDS).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

THN102 (Flecainide and Modafinil) Analytical Perspective

In-depth THN102 (Flecainide and Modafinil) Market Assessment

This report provides a detailed market assessment of THN102 (Flecainide and Modafinil) in Excessive Daytime Sleepiness (EDS) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

THN102 (Flecainide and Modafinil) Clinical Assessment

The report provides the clinical trials information of THN102 (Flecainide and Modafinil) in Excessive Daytime Sleepiness (EDS) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Excessive Daytime Sleepiness (EDS) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence THN102 (Flecainide and Modafinil) dominance.
• Other emerging products for Excessive Daytime Sleepiness (EDS) are expected to give tough market competition to THN102 (Flecainide and Modafinil) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of THN102 (Flecainide and Modafinil) in Excessive Daytime Sleepiness (EDS).
• Our in-depth analysis of the forecasted sales data of THN102 (Flecainide and Modafinil) from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the THN102 (Flecainide and Modafinil) in Excessive Daytime Sleepiness (EDS).

Key Questions Answered

• What is the product type, route of administration and mechanism of action of THN102 (Flecainide and Modafinil)?
• What is the clinical trial status of the study related to THN102 (Flecainide and Modafinil) in Excessive Daytime Sleepiness (EDS) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the THN102 (Flecainide and Modafinil) development?
• What are the key designations that have been granted to THN102 (Flecainide and Modafinil) for Excessive Daytime Sleepiness (EDS)?
• What is the forecasted market scenario of THN102 (Flecainide and Modafinil) for Excessive Daytime Sleepiness (EDS)?
• What are the forecasted sales of THN102 (Flecainide and Modafinil) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Excessive Daytime Sleepiness (EDS) and how are they giving competition to THN102 (Flecainide and Modafinil) for Excessive Daytime Sleepiness (EDS)?
• Which are the late-stage emerging therapies under development for the treatment of Excessive Daytime Sleepiness (EDS)?